# CJC-1295 Ipamorelin References: The Cited Research Record

> CJC-1295 Ipamorelin references: the full cited literature behind this review — PubMed-linked studies on the pharmacology, synergy, safety, and comparators, with DOIs and PMIDs.

Every quantitative claim on this site maps to one of these studies. DOIs and PubMed links included so you can verify each one.

## How to use this list

The CJC-1295 Ipamorelin references below are numbered to match the inline citation markers across the site. Items 1–6 are the core pharmacology, synergy, and safety studies that the review leans on most; items 7–12 provide comparator, mechanism-of-side-effect, and recent-appraisal context. Where a study used a related peptide (tesamorelin, MK-677) or a related model rather than the exact fixed blend, that is stated in the body text wherever the citation appears. No claim on this site is sourced to anything outside this list.

## References

[1] Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/
[2] Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. https://pubmed.ncbi.nlm.nih.gov/9849822/
[3] Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. https://pubmed.ncbi.nlm.nih.gov/2108187/
[4] Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. https://pubmed.ncbi.nlm.nih.gov/12446584/
[5] Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. https://pubmed.ncbi.nlm.nih.gov/15817669/
[6] Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28400207/
[7] Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. https://pubmed.ncbi.nlm.nih.gov/41545261/
[8] Chapman IM, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-57. https://pubmed.ncbi.nlm.nih.gov/8954023/
[9] Hoffman DM, et al. Short-term growth hormone (GH) treatment of GH-deficient adults increases body sodium and extracellular water, but not blood pressure. J Clin Endocrinol Metab. 1996;81(3):1123-8. https://pubmed.ncbi.nlm.nih.gov/8772586/
[10] Lall S, et al. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-8. https://pubmed.ncbi.nlm.nih.gov/11162489/
[11] Tausendfreund O, et al. Growth hormone treatment in aged patients with comorbidities: A systematic review. Growth Horm IGF Res. 2024;76:101584. https://pubmed.ncbi.nlm.nih.gov/38489867/
[12] Renke G, et al. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Int J Mol Sci. 2026;27(9):3890. https://pubmed.ncbi.nlm.nih.gov/42123471/

---

A calibrated reading of the CJC-1295 and ipamorelin literature — the measured findings logged to source, the untested fixed blend kept honestly apart, and the empty long-term-safety line left openly unfilled; not a clinic, not a vendor, not a prescription.